A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Recruiting · Phase 3 · NCT06810505

Conditions: Chronic Migraine

Research payments reported, 2025: $643,739
U.S. investigators named: 30
Sites paid: 46
Planned or actual enrollment: 420

About the trial

Sponsor: AbbVie
Tested: Atogepant (drug), Placebo for Atogepant (drug)
Dates: Started 2025-02-13; completion 2031-03
Results posted: Not yet

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chro…

From ClinicalTrials.gov, last updated 2026-10-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $643,739 in research payments for this study in 2025 (189 payments).

Products named: Qulipta

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it